Non-small cell lung cancer: an update on emerging EGFR-targeted therapies

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Epidermal Growth Factor Receptor (EGFR) mutations are key drivers in non-small cell lung cancer (NSCLC).
• Managing drug resistance and addressing uncommon mutations are critical challenges in EGFR-mutated NSCLC treatment.
• Extending targeted therapies to earlier stages of NSCLC is an active area of research.

Purpose of the Study:

• To provide a comprehensive overview of current and novel treatment strategies for EGFR-mutated NSCLC.
• To highlight promising new therapeutic approaches, including combination therapies.
• To identify challenges and future directions in the management of EGFR-mutated NSCLC.

Main Methods:

• Literature review of the PubMed database.
• Analysis of recruiting phase II-III clinical trials from ClinicalTrials.gov.
• Focus on trials involving EGFR-mutated NSCLC in both early and advanced stages.

Main Results:

• Current research addresses drug resistance and uncommon EGFR mutations in NSCLC.
• New strategies involve combination therapies, such as EGFR-TKIs with chemotherapy (e.g., FLAURA2) or drugs targeting other pathways (e.g., MARIPOSA).
• Clinical trials are exploring novel treatment paradigms for EGFR-mutated NSCLC.

Conclusions:

• An exhaustive overview of current and potential treatments for EGFR-mutated NSCLC is presented.
• Emphasis is placed on combination therapies and personalized treatment approaches.
• Future efforts should focus on optimizing existing compounds, managing toxicities, and deepening biological understanding for rational trial design and personalized medicine.